In many cases the same genetic alteration can be driving breast cancer in one patient, and lung cancer in another, opening up for many more treatment options.
Genetic testing using sequencing, opens up for treating with new types of drugs that target these genetic changes. Often the test can identify a less toxic and more effective targeted treatment with less side effects.
OneRNA™ can assist you in selecting the right patients for your clinical trial. Reducing the number of different test to ONE, without compromising the number of markers you want to include. In fact you can have it all +20,000 RNA’s in ONE assay. Furthermore adding a new marker is a simple update to our cloud-based software which we can do retrospectively. As such, OneRNA™is uniquely able to keep pace with rapidly evolving clinical research and cancer drug development. Finally we can help you focus on the right indication, expand your label on existing drugs, and create responder algorithms rather than relying on one marker as a companion diagnostic.
US Vice-President Joe Biden convenes international leaders in cancer research, cancer treatment and data science to discuss potential opportunities to advance the pace of progress in the fight against cancer.Speakers: Paula T. Hammond, Jennifer Doudna, Sylvia Mathews Burwell, Francis S. Collins, Joseph R. Biden Jr, Elizabeth Blackburn, Bill McDermott, Delos M. (Toby) Cosgrove, José Baselga, Charles Sawyers, David B. AgusTopics: Health, Fourth Industrial Revolution